For people born with the highest genetic risk for Alzheimer’s disease, a small oral drug may finally be slowing the clock. In a Phase III trial of 325 participants, valiltramiprosate (also known as ALZ-801) did not significantly improve symptoms across all patients with early Alzheimer’s. But in those still at the mild cognitive impairment (MCI) stage, the drug appeared to cut memory decline by more than half while slowing the shrinkage of the brain’s hippocampus, the memory center most devastated by the disease.
The results, published in Drugs, come from the APOLLOE4 trial, a 78-week, randomized, double-blind study testing oral valiltramiprosate in APOE ε4/ε4 homozygotes, who face up to a 15-fold higher lifetime risk of Alzheimer’s than people without the variant. Investigators across multiple centers followed participants aged 50 to 80 years who met clinical criteria for early symptomatic disease, comparing 265 mg of valiltramiprosate twice daily against placebo.
A Genetic Subgroup Shows Promise
When the team analyzed all participants together, valiltramiprosate slowed cognitive decline on the ADAS-Cog13 by about 11 percent, a difference too small to reach statistical significance. But among those with MCI, defined by a Mini-Mental State Examination score above 26, the effect jumped to 52 percent on ADAS-Cog13, accompanied by significant preservation of hippocampal volume on MRI.
In those participants, the drug’s benefits extended beyond memory. The MCI subgroup showed a 96 percent slowing on the Disability Assessment for Dementia and a positive trend on the Clinical Dementia Rating-Sum of Boxes. Measures of tissue microstructure using MRI diffusion tensor imaging suggested better maintenance of both gray and white matter integrity. The findings, while still exploratory, point toward an early therapeutic window before irreversible neurodegeneration sets in.
“Oral valiltramiprosate may provide a favorable benefit–risk profile and simple treatment paradigm for homozygotes with MCI,” the authors concluded.
Researchers also found that individual improvements in cognition correlated closely with imaging measures of slowed atrophy, suggesting that the clinical signals were not statistical noise. This linkage between brain structure and function could strengthen the case for future confirmatory trials targeting patients even earlier in the disease trajectory.
Brain Protection Without Dangerous Side Effects
Valiltramiprosate works by preventing toxic beta-amyloid oligomers from forming, a strategy distinct from antibodies that remove existing amyloid plaques but often trigger brain swelling and microhemorrhages. In APOLLOE4, patients on valiltramiprosate experienced no increase in amyloid-related imaging abnormalities, indicating a cleaner safety profile. The most common side effects were nausea, vomiting, and reduced appetite, which occurred at roughly twice the rate seen in the placebo group.
These tolerability findings matter because APOE4 carriers are particularly sensitive to amyloid-targeting antibodies, which have shown both promise and risk in other trials. A safe oral agent could therefore complement or even replace intravenous therapies that require intensive monitoring and carry higher costs.
Still, experts caution against overinterpretation. The improvements in MCI were nominally significant, meaning they did not meet strict thresholds for statistical proof. As principal investigator Susan Abushakra and colleagues wrote, the results should be viewed as hypothesis-generating rather than definitive.
“The APOE4/4 early AD population did not show significant clinical efficacy at 78 weeks but showed significant brain atrophy slowing,” the paper reported.
Future trials, the authors suggest, should concentrate on individuals at the earliest detectable stages of Alzheimer’s, where the molecular cascade may still be reversible. Given the drug’s oral dosing and lack of amyloid-related edema, valiltramiprosate could become a practical, lower-risk option if future data confirm its efficacy.
For now, the study offers a rare hint of optimism for a population long left behind by Alzheimer’s drug research. The hope is that slowing hippocampal shrinkage today might translate into preserved memories tomorrow, especially for those whose genetics make prevention feel almost out of reach.
Drugs: 10.1007/s40265-025-01901-3
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.